αVβ8-IN-1
αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors[1].
Product Specifications
CAS Number
[3048440-55-4]
UNSPSC
12352005
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/αvβ8-in-1.html
Purity
96.31
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
OC([C@H](CCOCCCCC(N1)=CC=C2C1=NCCC2)NC(C3(C4=C(Cl)N=CN=C4C)CC3)=O)=O
Molecular Formula
C25H32ClN5O4
Molecular Weight
502.01
References & Citations
[1]Machajewski, timothy D, et al. alpha-v-beta-8 integrin inhibitors and uses thereof. US2023/085812. 2024.07.04.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
KLHL6, CT (KLHL6, Kelch-like protein 6) (MaxLight 650) discontinued
Human Monoclonal HGF Antibody (ficlatuzumab) [Janelia Fluor 585]